AI Screening Shortens Time to Eye Care for Diabetic Patients: Trial

The signal here is not the AI model itself but the bottleneck it targets: the handoff between screening and specialist care, where delays quietly erode outcomes. A randomized design gives this more weight than the usual retrospective screening-accuracy studies, and it lands in a clinical workflow — publicly funded eye screening — that is capacity-constrained and already strained by diabetic caseloads. Whether the interval gains hold outside a trial setting, and whether specialist capacity absorbs a faster inflow, is the open question worth tracking.